Rheumatology is a specialty without a headline item in this revision. No new or increased items specific to rheumatoid arthritis management were identified.
Two things determine revenue movement: the cross-specialty items (consultation fees, inflation add-on, wage increase evaluation fee), and how far biosimilar policy is pushed.
1. What changed
| Item | Change | Old → New | Impact |
|---|---|---|---|
| Rheumatology-specific management fees and procedures | No new or increased items specific to rheumatoid arthritis management identified (impact is from cross-specialty items) | — | — |
| Biosimilar capacity add-on (inpatient) | Billing day moved from "admission day" to "discharge day." Volume requirement revised from total usage count to "50+ package units over the past year for at least one ingredient." Quantity share targets: 50%+ for infliximab, etanercept, and adalimumab; 80%+ for rituximab | 100 pts (points unchanged, billing day changed) (verify) | Medium |
| Biosimilar introduction add-on (outpatient) | Continues (evaluates explanation on outpatient switching and initiation of biologics) | 150 pts (monthly, 3-month limit, unchanged) (verify) | Low |
| Biosimilar dispensing capacity add-on (new, pharmacy side) | New add-on where a pharmacy dispenses a biosimilar (excluding insulin). Affects biologics prescribed externally, including self-injection products such as etanercept and adalimumab biosimilars | 50 pts per prescription received (new, verify) | Medium (indirect) |
2. What it means for the practice
(1) Watch the billing timing change. The inpatient biosimilar capacity add-on moved from admission day to discharge day. Without updating the billing system setting, missed and incorrect claims follow.
(2) Planned biosimilar switching became a condition of holding the add-on. National quantity share targets are explicit (50%+ for adalimumab, etanercept, infliximab; 80%+ for rituximab), and the volume requirement moved from total usage count to a package-unit quantity basis. Build a formulary and prepare patient explanation materials — it matters both for holding the add-on and for avoiding negative drug margins.
(3) External prescribing now works in your favour via pharmacies. With a 50-point biosimilar dispensing add-on created on the pharmacy side, partner pharmacies have more reason to stock biosimilars and cooperate on switching. If you prescribe self-injection products externally, coordinating with pharmacies in advance is worth more than it was.
(4) Patient cost support for high-cost biologics (high-cost medical expense benefit, home self-injection guidance) is unchanged; no specialty-specific change was identified.
3. Practical checklist
- (Inpatient) Has the billing day for the biosimilar capacity add-on been changed to discharge day?
- Do you meet the volume requirement (50+ package units over the past year for at least one ingredient)?
- Do you know your biosimilar quantity share for key ingredients against the 50% / 80% targets?
- Have you prepared patient explanation materials for switching from originators?
- If prescribing externally, have you shared stocking and switching plans with partner pharmacies?
4. Where an AI-native EMR fits — feature by feature
In a year with no upside from the rules, drug selection and billing precision decide results. Here is how Pottech's AI-native EMR helps, feature by feature.
Feature 1: Billing and claims management — follow the timing change
The automatic billing engine checks bundling, mutual exclusions, and frequency limits.
Moving from "admission day" to "discharge day" is the kind of change that becomes a missed claim unless the workflow changes with it. The biosimilar introduction add-on's monthly, three-month limit is similar: infrequent billing is what slips from memory. Keeping the billing logic in the system prevents these quiet losses.
Feature 2: Management analytics dashboard — hold biosimilar share as a metric
Visit volumes, revenue per patient, and monthly trends are aggregated and visualized automatically.
With quantity share targets now explicit, "what is our biosimilar share for adalimumab" is a management metric. Falling short risks the add-on's volume requirement; meeting it improves the drug cost structure. Tracking share by ingredient monthly is the switching plan's progress management.
Feature 3: Charting and orders — record the switching conversation
AI generates SOAP notes from the consultation audio, and set orders enter tests and prescriptions in one action.
Switching from an originator to a biosimilar is a change that requires patient buy-in. The biosimilar introduction add-on evaluates the explanation, and what was explained and how the patient responded is the evidence behind the claim. Having the record accumulate within the flow of the consultation is practical support for pushing switching forward.
Also review what applies to every specialty
For rheumatology, capturing the cross-specialty items is the main source of upside. See "what applies to every specialty."
Sources (principal)
- MHLW, "About the FY2026 Fee Schedule Revision" https://www.mhlw.go.jp/stf/newpage_67729.html
- Medical Care Support, "Biosimilar capacity add-on (FY2026)" https://medicalcare-support.jp/articles/biosimilar-shiyou-taisei-kasan-2026
- Tokyo Association of Medical Practitioners, "FY2026 revision: Chuikyo report (excerpt)" https://www.hokeni.org/docs/2026021200012/